Tiny AI projects with huge promise hiding in plain sight …

I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars.

Daniel J. Lippis net worth and biography

Daniel Lippis Biography and Net Worth

VP of Edwards Lifesciences

Daniel J. Lippis became corporate vice president, Japan, Greater China and Asia Pacific, in January 2024. Lippis has more than 25 years of sales, marketing, business operations and general management experience in the pharmaceutical and medical technology industries. Lippis joined Edwards in 2010 where he led marketing for the transcatheter heart valve (THV) business and subsequently oversaw the successful launches and therapeutic adoption of TAVR and the SAPIEN valve platforms in the U.S. and globally. Most recently, Lippis served as senior vice president of Europe THV where he led sustained growth of TAVR technology in a mature market, developed a high-touch field organization and championed diversity, inclusion and belonging efforts throughout the region. In 2022, his responsibilities were expanded to include business operations and regulatory affairs for Europe, Middle East, Africa, Canada and Latin America. Before joining Edwards, Lippis held sales and marketing leadership positions of increasing responsibility at Johnson & Johnson companies Biosense Webster Inc. and Cordis Inc. based in the United States, Europe, and Asia Pacific. He received a bachelor’s degree in science from the University of Adelaide with a double major in pharmacology and human physiology, and a post-graduate diploma in marketing from the University of Technology Sydney.

What is Daniel J. Lippis' net worth?: The estimated net worth of Daniel J. Lippis is at least $2.15 million as of May 7th, 2024. Mr. Lippis owns 23,890 shares of Edwards Lifesciences stock worth more than $2,152,728 as of May 16th. This net worth estimate does not reflect any other assets that Mr. Lippis may own. Learn More about Daniel J. Lippis' net worth.
How do I contact Daniel J. Lippis?: The corporate mailing address for Mr. Lippis and other Edwards Lifesciences executives is ONE EDWARDS WAY, IRVINE CA, 92614. Edwards Lifesciences can also be reached via phone at (949) 250-2500 and via email at [email protected]. Learn More on Daniel J. Lippis' contact information.
Has Daniel J. Lippis been buying or selling shares of Edwards Lifesciences?: Within the last three months, Daniel J. Lippis has sold $73,359.20 in Edwards Lifesciences stock. Most recently, Daniel J. Lippis sold 857 shares of the business's stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $85.60, for a transaction totalling $73,359.20. Following the completion of the sale, the vice president now directly owns 23,890 shares of the company's stock, valued at $2,044,984. Learn More on Daniel J. Lippis' trading history.
Who are Edwards Lifesciences' active insiders?: Edwards Lifesciences' insider roster includes Donald Bobo, Jr (VP), Daveen Chopra (VP), Kieran Gallahue (Director), Leslie Heisz (Director), Jean-Luc Lemercier (VP), Daniel Lippis (VP), Martha Marsh (Director), Michael Mussallem (CEO), Robert Sellers (VP), Catherine Szyman (VP), Scott Ullem (CFO), Nicholas Valeriani (Director), Huimin Wang (VP), Larry Wood (VP), and Bernard Zovighian (VP). Learn More on Edwards Lifesciences' active insiders.
Are insiders buying or selling shares of Edwards Lifesciences?: In the last year, Edwards Lifesciences insiders bought shares 1 times. They purchased a total of 580 shares worth more than $49,729.20. In the last year, insiders at the medical research company sold shares 60 times. They sold a total of 700,049 shares worth more than $56,544,740.20. The most recent insider tranaction occured on May, 10th when VP Donald E Bobo Jr sold 5,000 shares worth more than $439,050.00. Insiders at Edwards Lifesciences own 1.3% of the company. Learn More about insider trades at Edwards Lifesciences.
Information on this page was last updated on 5/10/2024.

Daniel J. Lippis Insider Trading History at Edwards Lifesciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/7/2024	Sell	857	$85.60	$73,359.20	23,890
3/7/2024	Sell	1,715	$90.98	$156,030.70	17,213

Daniel J. Lippis Buying and Selling Activity at Edwards Lifesciences

Edwards Lifesciences Company Overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Today's Range

Now: $90.11

$89.95

$90.98

50 Day Range

MA: $90.10

$84.23

$95.56

2 Week Range

Now: $90.11

$60.57

$96.12

Volume

2,181,357 shs

Average Volume

3,640,887 shs

Market Capitalization

$54.30 billion

P/E Ratio

38.84

Dividend Yield

N/A

Beta

1.1

Tiny AI projects with huge promise hiding in plain sight …

From Weiss Ratings | Ad